Recurrence of ROP (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (unit of analysis: eyes) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Quality of life · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality, relapse and progresses (instead of disease‐ or relapse‐free survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality, relapse and progresses (instead of disease‐ or… compared with chemotherapy only (moderate certainty).
1 finding from 1 review
On‐study mortality · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in on‐study mortality compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Severe adverse effects (grade 3+): Infection · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in infection grade III/IV compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes diarrhoea grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes nausea/vomiting grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Cardiac toxicity grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Quality of life (Change from baseline to week 15)
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
1 finding from 1 review
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review
Maternal mortality due to bleeding · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid showed no clear difference in maternal mortality due to bleeding compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Maternal mortality ‐ not reported · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid showed no clear difference in maternal mortality (all causes) compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Serious maternal morbidity · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid showed no clear difference in serious maternal morbidity (any) compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Maternal blood loss of 500 mL or greater · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid may leads to lower blood loss 500 mL or more after randomisation compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Blood transfusion · women with primary postpartum haemorrhage following vaginal or caesarean birth
Standard care plus IV tranexamic acid showed no clear difference in blood transfusion (any) compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review